In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units. 1998

G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
Istituto di Microbiologia, Università di Catania, Italia.

From May 1996 to September 1997, 615 Pseudomonas aeruginosa strains isolated from patients in intensive care units collected from different Italian laboratories were studied. The susceptibility of piperacillin/tazobactam, in comparison with other antipseudomonal antibiotics, to their NCCLS breakpoints was evaluated: amikacin 79. 6%, carbenicillin 67.0%, ceftazidime 73.4%, ciprofloxacin 55.8%, imipenem 64.1%, piperacillin 88.1%, piperacillin/tazobactam 92.4% and ticarcillin/clavulanic acid 69.0%. Seventy-three strains were selected because of their resistance to piperacillin and the mechanisms underlying such a resistance were investigated. Isoelectric focusing and hydrolysis assays revealed the presence of 15 plasmid-mediated beta-lactamases. Chromosomal beta-lactamase derepression was demonstrated in 34 isolates. The remaining 24 piperacillin-resistant strains did not produce beta-lactamases and an 'intrinsic mechanism' of resistance was inferred. The piperacillin/tazobactam combination restored resistance in 25 piperacillin strains. Nine of these were derepressed for chromosomal beta-lactamase, 8 showed impermeability and 8 showed plasmid enzymes.

UI MeSH Term Description Entries
D007362 Intensive Care Units Hospital units providing continuous surveillance and care to acutely ill patients. ICU Intensive Care Units,Intensive Care Unit,Unit, Intensive Care
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010397 Penicillanic Acid A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed) Acid, Penicillanic
D010403 Penicillin Resistance Nonsusceptibility of an organism to the action of penicillins. Penicillin Resistances,Resistance, Penicillin,Resistances, Penicillin
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D010878 Piperacillin Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics. AB-Piperacillin,Cl-227193,Pipcil,Pipera-Hameln,Piperacillin Curasan,Piperacillin Fresenius,Piperacillin Hexal,Piperacillin Monosodium Salt,Piperacillin Sodium,Piperacillin-Ratiopharm,Pipercillin,Pipracil,Pipril,T-1220,T1220,AB Piperacillin,Cl 227193,Cl227193,Curasan, Piperacillin,Monosodium Salt, Piperacillin,Pipera Hameln,Piperacillin Ratiopharm,Salt, Piperacillin Monosodium,Sodium, Piperacillin,T 1220
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
November 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
January 2009, Interdisciplinary perspectives on infectious diseases,
G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
December 2003, Chemotherapy,
G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
September 2015, Diagnostic microbiology and infectious disease,
G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
May 1991, Pathologie-biologie,
G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
April 2004, Chemotherapy,
G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
March 2008, The Journal of antimicrobial chemotherapy,
G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
October 2004, Mikrobiyoloji bulteni,
G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
August 1984, Antimicrobial agents and chemotherapy,
G Bonfiglio, and Y Laksai, and N Franceschini, and M Perilli, and B Segatore, and C Bianchi, and S Stefani, and G Amicosante, and G Nicoletti
July 2021, Clinical pharmacokinetics,
Copied contents to your clipboard!